Breast

Primary Site Histology
C500-C506, C508-C509 8000-8700, 8982-8983
C501-C506, C508-C509 8720-8790

Notes

8000-8700, 8720-8790 [except C500], 8982-8983 C500 Nipple C501 Central portion of breast C502 Upper-inner quadrant of breast C503 Lower-inner quadrant of breast C504 Upper-outer quadrant of breast C505 Lower-outer quadrant of breast C506 Axillary Tail of breast C508 Overlapping lesion of breast C509 Breast, NOS **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 48 *Breast*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **Other EOD Schemas with Breast sites** * **GIST**: 8935-8936 * **Kaposi Sarcoma**: 9140 * **Melanoma Skin (C500 only)**: 8720-8790 * **Mycosis Fungoides**: 9700-9701 * **Soft Tissue Other**: 8992 * **Soft Tissue Rare**: 8804-8806, 8930-8931, 8991, 9020, 9044, 9231, 9581 * **Soft Tissue Trunk and Extremities**: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8940-8981, 8990, 9000-9016, 9030-9043, 9045-9138, 9141-9230, 9240-9580, 9582 **Note 3:** **Additional data items for stage** * In addition to coding *EOD Primary Tumor, EOD Regional Nodes* and *EOD Mets*, the following data items are also needed to assign a stage group for Breast. * ER Summary * PR Summary * HER2 Summary * Oncotype Dx Recurrence Score

Data Items

Name Default Value Used in Derivation NAACCR Item Required By Metadata
Year of Diagnosis No NAACCR #390
dateOfDiagnosis
None
Primary Site Yes NAACCR #400
primarySite
None
Histology Yes NAACCR #522
histologicTypeIcdO3
None
Behavior Yes NAACCR #523
behaviorCodeIcdO3
None
Type of Reporting Source No NAACCR #500
typeOfReportingSource
None
Tumor Size Clinical No NAACCR #752
tumorSizeClinical
None
Tumor Size Pathological No NAACCR #754
tumorSizePathologic
None
Tumor Size Summary 999 No NAACCR #756
tumorSizeSummary
None
Regional Nodes Positive 99 No NAACCR #820
regionalNodesPositive
None
Regional Nodes Examined 99 No NAACCR #830
regionalNodesExamined
None
Sentinel Lymph Nodes Positive 99 No NAACCR #835
sentinelLymphNodesPositive
None
Sentinel Lymph Nodes Examined 99 No NAACCR #834
sentinelLymphNodesExamined
None
Neoadjuvant Therapy 9 No NAACCR #1632
neoadjuvantTherapy
None
Neoadjuvant Therapy – Clinical Response 9 No NAACCR #1633
neoadjuvTherapyClinicalResponse
None
Neoadjuvant Therapy – Treatment Effect 9 No NAACCR #1634
neoadjuvTherapyTreatmentEffect
None
EOD Primary Tumor 999 Yes NAACCR #772
eodPrimaryTumor
None
EOD Regional Nodes 999 Yes NAACCR #774
eodRegionalNodes
None
EOD Mets 00 Yes NAACCR #776
eodMets
None
SS2018 No NAACCR #764
summaryStage2018
None
Grade Clinical 9 Yes NAACCR #3843
gradeClinical
All SSDI
Grade Pathological 9 Yes NAACCR #3844
gradePathological
All SSDI
Grade Post Therapy Clin (yc) No NAACCR #1068
gradePostTherapyClin
COC
NPCR
SEER
SSDI
Grade Post Therapy Path (yp) No NAACCR #3845
gradePostTherapy
CCCR/Canada
COC
NPCR
SEER
SSDI
Lymph Nodes Positive Axillary Level I-II X8 No NAACCR #3882
lnPositiveAxillaryLevel1To2
COC
SEER
SSDI
ER Summary 9 No NAACCR #3827
estrogenReceptorSummary
CCCR/Canada
COC
NPCR
SEER
SSDI
ER Percent Positive XX8 No NAACCR #3826
estrogenReceptorPercntPosOrRange
COC
SEER (RC)
SSDI
PR Summary 9 No NAACCR #3915
progesteroneRecepSummary
CCCR/Canada
COC
NPCR
SEER
SSDI
PR Percent Positive XX8 No NAACCR #3914
progesteroneRecepPrcntPosOrRange
COC
SEER (RC)
SSDI
HER2 Overall Summary 9 No NAACCR #3855
her2OverallSummary
CCCR/Canada
COC
NPCR
SEER
SSDI
Ki-67 (MIB-1) XXX.8 No NAACCR #3863
ki67
COC
SEER (RC)
SSDI
Oncotype DX Recur Score - Invasive XX9 No NAACCR #3904
oncotypeDxRecurrenceScoreInvasiv
CCCR/Canada
COC
SEER
SSDI
Oncotype DX Recur Score - DCIS XX8 No NAACCR #3903
oncotypeDxRecurrenceScoreDcis
COC
SEER (RC) 2018–2025
SSDI
Multigene Signature Method 8 No NAACCR #3894
multigeneSignatureMethod
COC
SEER 2018–2025
SSDI
Multigene Signature Result X8 No NAACCR #3895
multigeneSignatureResults
COC
SEER 2018–2025
SSDI
Response Neoadjuv Therapy 8 No NAACCR #3922
responseToNeoadjuvantTherapy
COC
SEER (RC)
SSDI
Residual Cancer Burden (RCB) X.888 No NAACCR #1178
residualCancerBurdenRCB
COC 2026–
SEER (RC) 2026–
SSDI 2026–
RCB Class 8 No NAACCR #1179
rcbClass
COC 2026–
SEER (RC) 2026–
SSDI 2026–
Oncotype Dx Risk Level - Invasive 8 No NAACCR #3906
oncotypeDxRiskLevelInvasive
COC 2018–2025
SEER (RC) 2018–2025
SSDI 2018–2025
Oncotype Dx Risk Level - DCIS 8 No NAACCR #3905
oncotypeDxRiskLevelDcis
COC 2018–2025
SEER (RC) 2018–2025
SSDI 2018–2025
ER Allred Score X8 No NAACCR #3828
estrogenReceptorTotalAllredScore
COC 2018–2022
SEER (RC) 2018–2022
SSDI 2018–2022
PR Allred Score X8 No NAACCR #3916
progesteroneRecepTotalAllredScor
COC 2018–2022
SEER (RC) 2018–2022
SSDI 2018–2022
HER2 IHC Summary 8 No NAACCR #3850
her2IhcSummary
CCCR/Canada 2018–2020
COC 2018–2020
SEER (RC) 2018–2020
SSDI 2018–2020
HER2 ISH Summary 8 No NAACCR #3854
her2IshSummary
CCCR/Canada 2018–2020
COC 2018–2020
SEER (RC) 2018–2020
SSDI 2018–2020
HER2 ISH DP Ratio XX.8 No NAACCR #3852
her2IshDualProbeRatio
COC 2018–2020
SEER (RC) 2018–2020
SSDI 2018–2020
HER2 ISH DP Copy No XX.8 No NAACCR #3851
her2IshDualProbeCopyNumber
COC 2018–2020
SEER (RC) 2018–2020
SSDI 2018–2020
HER2 ISH SP Copy No XX.8 No NAACCR #3853
her2IshSingleProbeCopyNumber
COC 2018–2020
SEER (RC) 2018–2020
SSDI 2018–2020

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Outputs

Name Default Value Description NAACCR Item Metadata
Schema ID 00480 NAACCR #3800
schemaId
None
Derived Version {{ctx_alg_version}} None None
Derived Summary Stage 2018 9 NAACCR #762
derivedSummaryStage2018
None
Derived Summary Grade 2018 <BLANK> NAACCR #1975
derivedSummaryGrade2018
None